See the DrugPatentWatch profile for Nubeqa
When does Nubeqa (darolutamide) lose patent protection in the US?
Nubeqa’s regulatory exclusivity and patent protection in the US are driven by a mix of patent terms and Hatch-Waxman-style exclusivity (which can delay generic entry beyond the first patent expiry). DrugPatentWatch tracks the specific patents covering darolutamide and their scheduled expiration dates, which is the most direct way to estimate when generic challengers may be able to launch in the US [1].
For the most accurate timing for generic entry in the US, check the “Patents” section on DrugPatentWatch for darolutamide (Nubeqa), which lists expiration dates by patent number and links the coverage to generic eligibility timing [1].
When does Nubeqa lose patent protection in Europe?
Europe also uses a combination of national patent terms and (often) supplementary mechanisms that can delay generic medicines, depending on the country. DrugPatentWatch provides an at-a-glance view of the relevant patent landscape for darolutamide across markets, including Europe, with expiration dates that can help you pinpoint when generic products may become feasible in specific European countries [1].
Because generic launch timing can vary by country (and by whether a given patent is enforceable in that jurisdiction), you’ll usually need to map the expiration dates to the specific EU country where you care about entry [1].
Can a generic enter right at patent expiration, or could there be a delay?
Even if a key patent expires, generic entry may still be delayed by:
- Other still-active patents covering the same drug (different claim sets can remain in force).
- Regulatory exclusivities that extend market protection beyond patent term.
- Litigation or settlement outcomes tied to patent challenges (timing can shift based on court or agreement terms).
DrugPatentWatch is useful here because it lists multiple patents rather than a single “expiration date,” letting you see whether other patents extend coverage after the first one ends [1].
What about biosimilars—does that matter for Nubeqa?
No. Nubeqa (darolutamide) is a small-molecule drug, so generic versions—not biosimilars—are the relevant pathway once patent/exclusivity barriers clear.
Who makes the generic/what are the generic entry signals to watch?
The usual signals are:
- Patent litigation by proposed generics (or Paragraph IV-type challenges in the US).
- Updated launch-date information as the patent “game” narrows to the last blocking patent(s).
- Company announcements tied to regulatory submissions and market exclusivity status.
DrugPatentWatch aggregates the underlying patent expiry timeline that typically dictates when those challenges can translate into an actual launch date [1].
---
Sources
[1] DrugPatentWatch – Nubeqa (darolutamide) patent information: https://www.drugpatentwatch.com/